API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-10-2024-93939.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217231
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215663
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205976
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-topiramate-extended-release-capsules-39359.pdf
https://health.economictimes.indiatimes.com/news/pharma/zydus-launches-topiramate-extended-release-capsules-for-epilepsy/96788498
https://www.prnewswire.com/news-releases/qsymia-phentermine-topiramate-drug-insights-and-market-forecasts-to-2032-301712347.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208949
https://pink.pharmaintelligence.informa.com/PS146955/Use-of-Gynecological-Drugs-Restricted-In-EU-Urgent-Safety-Review-Starts-For-Pholcodine
https://www.ema.europa.eu/en/news/prac-starts-review-topiramate-use-pregnancy-women-childbearing-potential
https://endpts.com/icer-reaffirms-qsymia-as-most-cost-effective-obesity-treatment-in-final-report/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215638
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215663
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-1-2021-1638337020.pdf
https://www.europeanpharmaceuticalreview.com/news/165242/aimovigdisplays-superiority-over-topiramate-in-migraine-study/
https://www.pharmaceutical-technology.com/news/fda-eton-azurity-eprontia-seizures/
https://www.prnewswire.com/news-releases/azurity-pharmaceuticals-inc-announces-fda-approval-of-eprontia-topiramate-oral-solution-301417993.html
https://www.globenewswire.com/news-release/2021/11/08/2329012/0/en/Eton-Pharmaceuticals-and-Azurity-Pharmaceuticals-Inc-Announce-FDA-Approval-of-EPRONTIA-topiramate-Oral-Solution.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215414
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210278
https://www.prnewswire.com/in/news-releases/glenmark-pharmaceuticals-receives-anda-approval-for-topiramate-extended-release-capsules-25-mg-50-mg-100-mg-150-mg-and-200-mg-859397600.html
https://www.nasdaq.com/press-release/eton-pharmaceuticals-announces-acceptance-for-filing-of-new-drug-application-for-1
https://www.nasdaq.com/press-release/eton-pharmaceuticals-announces-acceptance-for-filing-of-new-drug-application-for-1
https://pharmaphorum.com/news/novartis-aimovig-tops-topiramate-in-migraine-face-off/?utm_source=pharmaphorum+Daily+Newsletter&utm_campaign=c8ccf15e4e-EMAIL_CAMPAIGN_2019_09_24_10_10_COPY_01&utm_medium=email&utm_term=0_a54496134b-c8ccf15e4e-443826894
https://www.globenewswire.com/news-release/2020/03/17/2001825/0/en/Eton-Pharmaceuticals-Reports-Positive-Study-Results-for-ET-101-Topiramate-Oral-Solution.html
https://www.fiercebiotech.com/research/fighting-obesity-by-attacking-both-food-intake-and-energy-burn?utm_source=internal&utm_medium=rss
https://www.fiercepharma.com/marketing/prescription-drug-police-ding-vivus-for-misleading-qsymia-obesity-treatment-webpage
https://www.raps.org/news-and-articles/news-articles/2019/5/opdp-issues-second-untitled-letter-of-2019
https://www.business-standard.com/article/companies/glenmark-pharma-gets-usfda-nod-for-seizure-treatment-drug-119012400247_1.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210278
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205976
https://www.biospace.com/article/supernus-pharma-to-buy-biscayne-neurotherapeutics-in-potential-183-million-deal-am6a-/?s=79
https://endpts.com/a-new-avenue-for-diet-pill-makers-uc-san-diego-researchers-uncover-root-of-leptin-resistance/
https://endpts.com/with-debt-looming-browbeaten-diet-pill-maker-orexigen-goes-bankrupt/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207382
http://www.pharmatimes.com/news/new_migraine_results_for_both_allergen_and_novartis_1204968
http://www.prnewswire.com/news-releases/upsher-smith-launches-newly-designed-website-for-qudexy-xr-topiramate-extended-release-capsules-300506940.html
http://www.prnewswire.com/news-releases/fda-approves-expanded-indication-for-qudexy-xr-topiramate-extended-release-capsules-to-include-prophylaxis-of-migraine-headache-in-adults-and-adolescents-300431866.html
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cadila-inks-pact-with-supernus-pharma-to-settle-patent-issue/articleshow/57512394.cms
https://www.pharma-excipients.ch/2017/03/08/topiramate-extended-release-options-a-focus-onefficacy-and-safety-in-epilepsy-and-comorbidities/
https://globenewswire.com/news-release/2016/12/12/897034/0/en/Supernus-Wins-Appeal-Case-on-Oxtellar-XR.html
http://www.pharma-excipients.ch/2016/11/08/trial-of-amitriptyline-topiramate-and-placebo-for-pediatric-migraine/
http://www.prnewswire.com/news-releases/upsher-smith-launches-its-that-simple-program-for-qudexy-xr-topiramate-extended-release-capsules-300324281.html
http://www.prnewswire.com/news-releases/upsher-smith-granted-tentative-fda-approval-for-qudexy-xr-topiramate-extended-release-capsules-for-prophylaxis-of-migraine-headache-in-adults-300282668.html
http://cphi-online.com/future-obesity-drugs-must-provide-improved-news038407.html
http://www.fiercepharma.com/story/vivus-counts-25m-q3-sales-300m-debt-how-can-it-possibly-cover-200m-plus-qsy/2015-11-05
http://www.fiercepharma.com/story/icahn-casts-his-eye-vivus-tender-offer-convertible-notes/2015-09-09
http://www.fiercepharmamarketing.com/story/brutal-honesty-drug-marketing-obesity-meds-its-key-avoiding-magic-pill-trap/2015-06-08